Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure.

CONCLUSION: Patients with higher-risk MDS in whom azacitidine treatment has failed have a poor prognosis and low probability of response to salvage treatments. The standard of care after azanucleoside failure should be enrollment in clinical trials.
PMID: 24054159 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - September 17, 2013 Category: Cancer & Oncology Authors: Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS Tags: Clin Lymphoma Myeloma Leuk Source Type: research